Sun Pharmaceutical, Cassiopea SpA sign license, supply agreements for Winlevi
26th Jul 2021

Sun Pharmaceutical Industries includes its subsidiaries and Cassiopea SpA have signed license and supply agreements for Winlevi (clascoterone cream 1%) in the United States and Canada. Winlevi has been approved by the United States Food & Drug Administration (FDA) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.

Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi in the United States and Canada, and Cassiopea will be the exclusive supplier of the product. Cassiopea will receive an upfront payment of $45 million, potential commercial milestones totalling up to US $190 million and customary double-digit royalties. The agreements will close upon the expiration of the HSR waiting period.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.